Clinical Report: Earlier Detection of Organ Rejection

Overview

Donor-derived cell-free DNA (dd-cfDNA) testing provides a noninvasive method for early detection of solid organ transplant injury, outperforming traditional methods. This review highlights the clinical utility of dd-cfDNA in kidney and heart transplantation, emphasizing its role in monitoring graft health and reducing unnecessary biopsies.

Background

The ability to detect organ rejection early is crucial for improving transplant outcomes and patient management. Traditional methods, such as serum chemistries and biopsies, may not identify rejection until significant damage has occurred. The introduction of dd-cfDNA testing represents a significant advancement in transplant diagnostics, allowing for timely interventions.

Data Highlights

No specific numerical data provided in the source material.

Key Findings

• dd-cfDNA levels are low under stable conditions but rise significantly during graft injury.
• Next-generation sequencing and droplet digital PCR are the two main analytical approaches for dd-cfDNA testing.
• In kidney transplantation, dd-cfDNA can differentiate active rejection from stable graft function, potentially reducing unnecessary biopsies.
• In heart transplantation, dd-cfDNA is utilized in surveillance strategies to rule out significant rejection in stable patients.
• Emerging applications of dd-cfDNA are being explored in liver and lung transplantation, though data remain less definitive.

Clinical Implications

Clinicians should consider incorporating dd-cfDNA testing into routine monitoring of transplant recipients, particularly in cases of graft dysfunction. This approach may enhance the ability to detect rejection earlier and tailor surveillance strategies to individual patient needs.

Conclusion

The adoption of dd-cfDNA testing marks a paradigm shift in transplant diagnostics, facilitating earlier detection of rejection and improved management of graft health. As evidence and standardization of assays grow, dd-cfDNA is expected to become integral to transplant laboratory medicine.

References

1. Keck Medicine of USC, Can a New Tool Better Screen Liver Transplant Candidates?, 2023 -- Can a New Tool Better Screen Liver Transplant Candidates?
2. Journal of Gastroenterology, Evidence of Activated CD8+ T Cell Migration Through Portal Vein Endothelial Cells During Liver Graft Rejection, 2016 -- Evidence of Activated CD8+ T Cell Migration Through Portal Vein Endothelial Cells During Liver Graft Rejection
3. Hyperspectral Imaging Techniques for Assessing Early Function of Human Liver Transplants, 2024 -- Hyperspectral Imaging Techniques for Assessing Early Function of Human Liver Transplants
4. Basic Research in Cardiology, Inhibition of Acute Rejection in Mouse Heart Transplants Using STAT-1 Decoy Oligodeoxynucleotides, 2009 -- Inhibition of Acute Rejection in Mouse Heart Transplants Using STAT-1 Decoy Oligodeoxynucleotides
5. American Society of Transplant Surgeons, Updated Statement on Donor-Derived Cell-Free DNA, 2024 -- Updated Statement on Donor-Derived Cell-Free DNA
6. ISHLT, Molecular Tests Provide More Convenient, Personalized Monitoring of Heart Transplant Recipients, 2025 -- Molecular Tests Provide More Convenient, Personalized Monitoring of Heart Transplant Recipients
7. https://www.asts.org/docs/default-source/position-statements/asts-statement-on-donor-derived-cell-free-dna-%28dd-cfdna%29---updated-oct.-2024.pdf?sfvrsn=19314fd3_3
8. Molecular Tests Provide More Convenient, Personalized Monitoring of Heart Transplant Recipients | ISHLT